Related Experiment Video
Updated: Jul 10, 2025
06:42
Plasmonic Photothermal Cancer Therapy: Nanoparticle-embedded Tumor-tissue-mimicking Phantoms for Visualizing Photothermal Temperature Distribution
Published on: May 9, 2025
431
Plasmonic Nanoparticle-Enhanced Optical Techniques for Cancer Biomarker Sensing
Li Fu1, Cheng-Te Lin2,3,4, Hassan Karimi-Maleh5,6,7
1Key Laboratory of Novel Materials for Sensor of Zhejiang Province, College of Materials and Environmental Engineering, Hangzhou Dianzi University, Hangzhou 310018, China.
Biosensors
|November 24, 2023
Summary
Localized surface plasmon resonance (LSPR) nanotechnology enhances optical techniques for sensitive cancer biomarker detection. This approach shows great promise for improving cancer screening, diagnosis, and treatment monitoring.
Area of Science:
- Nanotechnology
- Biomedical Optics
- Cancer Diagnostics
Background:
- Localized Surface Plasmon Resonance (LSPR) is a phenomenon arising from noble metal nanoparticles under light excitation.
- LSPR enhances various optical techniques, offering new avenues for sensitive biomarker detection.
Purpose of the Study:
- To review recent advances in LSPR nanotechnology for cancer biomarker detection.
- To discuss nanoparticle engineering strategies for optimizing LSPR signal amplification.
- To examine the integration of LSPR techniques with microfluidics and point-of-care devices.
Main Methods:
- Surface-Enhanced Raman Spectroscopy (SERS) for molecular detection.
- Dark-Field Microscopy (DFM) for cellular and molecular imaging.
- Photothermal and Photoacoustic Imaging for tissue visualization.
- Nanoparticle engineering for signal enhancement.
Main Results:
- SERS enables single-molecule sensitivity for detecting proteins, nucleic acids, and exosomes.
- DFM allows ultrasensitive detection of cancer cells, microRNAs, and proteins.
- Photothermal and Photoacoustic imaging provide enhanced visualization of cancerous tissues.
- LSPR techniques demonstrate multiplexing capabilities.
Conclusions:
- LSPR nanotechnology holds significant potential for advancing cancer screening, diagnosis, and treatment monitoring.
- Integration with microfluidics and point-of-care platforms is crucial for clinical translation.
- Challenges including toxicity, standardization, and clinical sample analysis need to be addressed.
